Tag Archives: Allergan PLC

Allergan wraps up 2016 M&A with LifeCell buy for $2.9 billion; analysts lavish kudos all around

Dublin-based Allergan said on December 19, 2016 it would buy LifeCell, a regenerative medicine unit owned by privately held Acelity LP (San Antonio TX), for $2.9 billion in cash, bringing… Read more »

New Biogen pick for CEO inherits tough job; markets aren’t exactly enthralled–yet

Biogen Inc. (Cambridge MA) said Monday (December 19, 2016) it has named veteran biopharmaceutical executive Michel Vounatsos, head of the company’s commercial organization, its next chief executive. Mr. Vounatsos will succeed George Scangos, who announced earlier this… Read more »

Feds charge Heritage execs with price fixing; DOJ ringing out 2016 on a roll against Pharma offenses

The former chief executive and former president of generic drug company Heritage Pharmaceuticals Inc. (Eatontown, NJ) have been charged with conspiring to fix prices, the first charges in a continuing… Read more »

Novo Nordisk to cap price increases as drug costs face more scrutiny; do two drugmakers equal a trend?

With drug companies under fire over prices, the world’s largest insulin maker plans to limit increases and join competitors by introducing a model that ties the cost of medicines to… Read more »

Novartis slowly, quietly imploding; will Alcon, Amneal moves halt spiral?

Renewed whispers from Swiss drugmaker Novartis AG (Basel) that it could divest its struggling Alcon eyecare business reflect the latest step in dismantling former leader Dan Vasella’s vision of building… Read more »

Needing cash, Valeant in talks to sell stomach-drug unit in $10 billion deal; hedge-fund icon Bill Ackman finally has a good day

Valeant Pharmaceuticals International Inc. (Laval Quebec) is in advanced talks to sell a big stomach-drug business to Japan’s Takeda Pharmaceutical Co. for about $10 billion, a move seen easing pressure on Valeant over its… Read more »

Pfizer misses 3Q views but gets nod for Prevnar from China; Mao would scowl, but not Xi

More than a year after pulling its vaccines out of one of the world’s most challenging but lucrative drug markets, Pfizer has moved back into China with a thumbs up for top-selling… Read more »

Pfizer Wins Bidding War for Medivation; But Why Bother?

Pharmaceutical giant Pfizer Inc. (New York City) is paying $14 billion to buy Medivation Inc. (San Francisco), a biotech company that sells a high-priced prostate cancer medication discovered by UCLA, according to the… Read more »

Biogen’s 2Q Profit Crushes Views; CEO to Depart

Biogen Inc. (Cambridge MA) stock jumped Thursday after the drugmaker reported strong sales of some of its newest treatments for multiple sclerosis and hemophilia. The company’s net income and sales… Read more »

Pfizer Acquires Anacor Pharma for $5.2 Billion

Pfizer Inc. (New York City) is buying Anacor Pharmaceuticals Inc. (Palo Alto CA) in a $5.2 billion deal to add an eczema gel to its portfolio, just a month after… Read more »